RTP Mobile Logo
Breast Cancer Update, Issue 3, 2013
Released November 2013

Featuring interviews with Drs Harold J Burstein, Sunil Verma, Ruth O’Regan and Javier Cortes. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Breast cancer continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Assimilate new clinical trial evidence evaluating the role of mTOR inhibition in reversing resistance to trastuzumab and endocrine therapy into the therapeutic algorithm for patients with progressive ER-positive metastatic breast cancer.
    • Evaluate recently presented data supporting the extended use of adjuvant tamoxifen beyond 5 years for patients with ER-positive early breast cancer and, where appropriate, integrate these findings into clinical practice.
    • Use existing and emerging biomarkers to assess risk and individualize therapy for patients with invasive early breast cancer.
    • Demonstrate knowledge of emerging research data to guide the selection of chemotherapeutic agents/regimens for patients with metastatic breast cancer.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should review the CME information, listen to the audio MP3s, and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Burstein had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr VermaAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Novartis Pharmaceuticals Corporation, Roche Laboratories Inc. Dr O’ReganAdvisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Contracted Research: Genentech BioOncology. Dr CortesAdvisory Committee and Consulting Agreements: Celgene Corporation, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Speakers Bureau: Celgene Corporation, Eisai Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    November 2013
    Expiration date: November 2014

Acknowledge and close

Listen to audio:
Breast Cancer Update, Issue 3, 2013
Released November 2013

Featuring interviews with Drs Harold J Burstein, Sunil Verma, Ruth O’Regan and Javier Cortes. (Text and Audio Content)

Read print: